{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:42:40Z","timestamp":1788370960311,"version":"build-2803163510"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Acute radiation dermatitis is a common side-effect of radiotherapy in breast cancer and has a profound impact on patients\u2019 quality of life, due to pain and discomfort. The aim of this study is to compare the effect of \u03b2-sitosterol (Mebo) ointment to trolamine (Biafine) cream for the prevention and treatment of radiation dermatitis in breast cancer patients receiving adjuvant radiation therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>This is a prospective open-label randomized phase III study developed to assess the efficacy of 2 topical agents used for management of acute radiation dermatitis. Female breast cancer patients who needed a course of radiation therapy in our institution were enrolled and randomized into 2 groups 1 with Mebo ointment and 1 with Biafine cream. Both medications were applied twice per day during the whole period of treatment and skin reactions and related symptoms were assessed weekly during the entire course. Grading of skin reactions was done according to the Radiation Therapy Oncology Group grading system.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Between September 2015 and May 2017, a total of 161 patients were recruited for this trial. Mean age was similar for both groups (50.19\u00b112.57 vs. 51.73\u00b111.23, respectively, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.41). All other patients and treatment characteristics were similar in both groups, except for the use of boost (82.7% in the Biafine group vs. 36.7% in Mebo group, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.012). Analysis was done for reactions recorded before the beginning of the boost and for the entire course including the boost. Using univariate and multivariate analysis, there was no significant difference in grades 2 and 3 dermatitis between the 2 groups. However, the incidence of severe pruritus and severe local skin pain were both significantly reduced in the Mebo group (14.1% in Biafine vs. 2.9% in Mebo, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.016 for pruritus and 11.5% vs. 1.4%, respectively, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.02 for severe pain).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study showed no difference between Mebo and Biafine in the incidence and severity of breast skin dermatitis during radiation therapy. However, the use of Mebo ointment was associated with decreased severe pruritus and pain which could positively affect patient comfort and quality of life.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000460","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T22:05:00Z","timestamp":1528409100000},"page":"1257-1262","source":"Crossref","is-referenced-by-count":27,"title":["Randomized, Prospective, Open-label Phase III Trial Comparing Mebo Ointment With Biafine Cream for the Management of Acute Dermatitis During Radiotherapy for Breast Cancer"],"prefix":"10.1097","volume":"41","author":[{"given":"Fady B.","family":"Geara","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, American University of Beirut Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toufic","family":"Eid","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, American University of Beirut Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Zouain","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clemenceau Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranim","family":"Thebian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, American University of Beirut Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Andraos","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cleveland Clinic Florida, Weston, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirine","family":"Chehab","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, American University of Beirut Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ramia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, American University of Beirut Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Youssef","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, American University of Beirut Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef H.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, American University of Beirut Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3322\/CA.2007.0017","article-title":"Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues","volume":"58","author":"Smith","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jaad.2005.08.054","article-title":"Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006","volume":"54","author":"Hymes","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0167-8140(02)00060-9","article-title":"The radiotherapeutic injury\u2014a complex \u2018wound\u2019","volume":"63","author":"Denham","year":"2002","journal-title":"Radiother Oncol"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.soncn.2011.02.009","article-title":"Evidence-based skin care management in radiation therapy: clinical update","volume":"27","author":"McQuestion","year":"2011","journal-title":"Semin Oncol Nurs"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0360-3016(00)00782-3","article-title":"Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-13","volume":"48","author":"Fisher","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ijrobp.2010.05.065","article-title":"Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4)","volume":"81","author":"Neben-Wittich","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-20230903","first-page":"5343","article-title":"Topical management of acute radiation dermatitis in breast cancer patients: a systematic review and meta-analysis","volume":"37","author":"Haruna","year":"2017","journal-title":"Anticancer Res"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2217\/fon-2017-0359","article-title":"Prevention and treatment of radiation-induced acute dermatitis in head and neck cancer patients: a systematic review","volume":"14","author":"Iacovelli","year":"2018","journal-title":"Future Oncol"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2005.04.9148","article-title":"Phase III trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13","volume":"24","author":"Elliott","year":"2006","journal-title":"J Clin Oncol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00000637-200101000-00023","article-title":"Split-thickness skin graft donor site dressing: preliminary results of a controlled, clinical comparative study of MEBO and Sofra-Tulle","volume":"46","author":"Atiyeh","year":"2001","journal-title":"Ann Plast Surg"},{"key":"R14-20230903","first-page":"505","article-title":"Moist Exposed Burn Ointment (MEBO) in partial thickness burns-a randomized, comparative open mono-center study on the efficacy of dermaheal (MEBO) ointment on thermal 2nd degree burns compared to conventional therapy","volume":"13","author":"Hirsch","year":"2008","journal-title":"Eur J Med Res"},{"key":"R15-20230903","first-page":"79","article-title":"A comparative study of the wound healing properties of Moist Exposed Burn Ointment (MEBO) and silver sulphadiazine","volume":"22","author":"Jewo","year":"2009","journal-title":"Ann Burns Fire Disasters"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.burns.2011.09.022","article-title":"Moist occlusive dressing (Aquacel(R) Ag) versus moist open dressing (MEBO(R)) in the management of partial-thickness facial burns: a comparative study in Ain Shams University","volume":"38","author":"Mabrouk","year":"2012","journal-title":"Burns"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pain.2004.09.014","article-title":"Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints","volume":"113","author":"Paul","year":"2005","journal-title":"Pain"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pain.2005.09.033","article-title":"Categorising the severity of neck pain: establishment of cut-points for use in clinical and epidemiological research","volume":"119","author":"Fejer","year":"2005","journal-title":"Pain"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000211516","article-title":"Biafine applied on human epidermal wounds is chemotactic for macrophages and increases the IL-1\/IL-6 ratio","volume":"10","author":"Coulomb","year":"1997","journal-title":"Skin Pharmacology"},{"key":"R20-20230903","first-page":"94","article-title":"Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Current","volume":"17","author":"Salvo","year":"2010","journal-title":"Oncology"},{"key":"R21-20230903","first-page":"305","article-title":"Topical Biafine and Lipiderm for the prevention of radiation dermatitis: A randomized prospective trial","volume":"8","author":"Fenig","year":"2001","journal-title":"Oncol Rep"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1200\/JCO.2004.07.063","article-title":"Phase III randomized trial of Calendula Officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer","volume":"22","author":"Pommier","year":"2004","journal-title":"J Clin Oncol"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0305-4179(02)00075-X","article-title":"Benefit-cost analysis of moist exposed burn ointment","volume":"28","author":"Atiyeh","year":"2002","journal-title":"Burns"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00000637-200202000-00032","article-title":"Efficacy of moist exposed burn ointment in the management of cutaneous wounds and ulcers: a multicenter pilot study","volume":"48","author":"Atiyeh","year":"2002","journal-title":"Ann Plastic Surg"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01.BCR.0000085846.87585.B7","article-title":"Pain control in a randomized, controlled, clinical trial comparing moist exposed burn ointment and conventional methods in patients with partial-thickness burns","volume":"24","author":"Ang","year":"2003","journal-title":"J Burn Care Rehabil"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2016.12.023","article-title":"Does an integrated boost increase acute toxicity in prone hypofractionated breast irradiation? A randomized controlled trial","volume":"122","author":"Paelinck","year":"2017","journal-title":"Radiothe Oncol"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/jamaoncol.2015.2666","article-title":"Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation a randomized clinical trial","volume":"1","author":"Shaitelman","year":"2015","journal-title":"JAMA Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201812000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T04:00:50Z","timestamp":1693713650000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201812000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000460","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}